“…The following MAbs (monoclonal antibodies) were used: MEM-G/ 9, a mouse IgG1 specific for native HLA-G1 and HLA-G5 isoforms (Exbio, Prague, Czech Republic); 35 4H84, a mouse IgG1 anti-HLA-G free heavy chain (kindly provided by M. Mc Master, University of California, San Francisco, CA); 34,36 5A6G7, a mouse IgG1 specific for the intron 4-retaining part of both soluble HLA-G5 and HLA-G6; 37 TP25.99, a mouse IgG1 anti-HLA-A, -B, -C and -E but not anti-HLA-G (kindly provided by S. Ferrone, Roswell Park Cancer Institute, Buffalo, NY); 34,38 B1G6, a mouse IgG2a, anti-b2 microglobulin (Immunotech, France); B8.12.2, a mouse IgG2b anti-HLA-DR (Immunotech); GHI/75, a mouse IgG2b anti-ILT-2 (Pharmingen, San Diego, CA); Z199, a mouse IgG2b anti-NKG2A (Immunotech) and B-5-1-2 , a mouse IgG1 anti-a tubulin (Sigma Chemical Co.).…”